Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level | Zendy

Kouji Izumi | Zendy; WenJye Lin | Zendy; Hiroshi Miyamoto | Zendy; Chiung-Kuei Huang | Zendy; Aerken Maolake | Zendy; Yasuhide Kitagawa | Zendy; Yoshifumi Kadono | Zendy; Hiroyuki Konaka | Zendy; Atsushi Mizokami | Zendy; Mikio Namiki | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level

Author(s) -

Kouji Izumi,

WenJye Lin,

Hiroshi Miyamoto,

Chiung-Kuei Huang,

Aerken Maolake,

Yasuhide Kitagawa,

Yoshifumi Kadono,

Hiroyuki Konaka,

Atsushi Mizokami,

Mikio Namiki

Publication year - 2014

Publication title -

journal of cancer research and clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.338

H-Index - 94

eISSN - 1432-1335

pISSN - 0171-5216

DOI - 10.1007/s00432-014-1681-8

Subject(s) - hematology , prostate cancer , prostate specific antigen , medicine , prostate , oncology , antigen , cancer , immunology

Prostate-specific antigen (PSA) is a useful biomarker of prostate cancer (PCa). High-risk localized PCa is defined using T stage, Gleason score (GS), and PSA. However, PSA level defining high-risk PCa is at most 20 ng/mL. In PCa patients with high PSA, it is unclear whether PSA itself can be a prognostic factor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research